Email
Print-Friendly
SubscribeHIV Care Today
By Paul E. Sax, M.D.
June 13, 2011
In the recent post on the approval of generic Combivir -- and the lack of availability of generic Epivir (lamivudine, 3TC), which was both anticipated and likely to be more useful -- I speculated there were several possible causes of this surprising turn of events.
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
June 9, 2011
If your patient population is anything like mine, then you see a lot of active drug users. My dear friend, Suzanne Carlberg-Racich, Ph.D., M.S.P.H., reminded me of my faux pas immediately after the article was published. I'd like to share the ensuing conversation with you, because it includes some very good tips.
By Paul E. Sax, M.D.
June 4, 2011
Periodically I like to give an informal quiz to the medical students about HIV epidemiology. It's a multiple choice question that goes something like this:
By Paul E. Sax, M.D.
May 26, 2011
FDA granted approval for a generic formulation fixed dose combination of lamivudine and zidovudine tablets, 150 mg/300 mg, two nucleoside analogue reverse transcriptase inhibitors, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection ... FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Combivir Tablets...
By Paul E. Sax, M.D.
May 23, 2011
FDA approved Edurant (rilpivirine) 25 mg tablets, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Rilpivirine is an antiviral drug that helps to block reverse transcriptase, an enzyme necessary for HIV replication. The recommended dose of rilpivirine is one 25 mg tablet once daily taken orally with a meal.
By Paul E. Sax, M.D.
May 18, 2011
Maybe I'm being presumptuous here, but one of these -- virologic suppression -- completely blows the rest of them away. Sure, the others are worthwhile, but data linking them to improved outcomes for people with HIV are either pretty weak (adherence counseling, flu vaccine) or nonexistent (toxoplasmosis serology).
By Paul E. Sax, M.D.
May 12, 2011
The results of the HPTN Study 052 -- which randomized 1,763 serodiscordant couples to early vs delayed ART to evaluate whether this reduced the risk of HIV transmission -- have just been released:
By Nelson Vergel, B.S.Ch.E., M.B.A.
May 3, 2011
"Deep salvage patients no longer exist. The ones in that situation are already dead or have responded to the latest HIV antiretrovirals."
By Paul E. Sax, M.D.
April 25, 2011
There's a new antiretroviral option out there, a 400-mg extended-release tablet formulation of nevirapine that can be dosed once daily.
By Paul E. Sax, M.D.
April 18, 2011
On the heels of last month's report of HIV transmission from an organ donor -- covered here in Journal Watch -- comes this remarkable article in The New York Times about lifting the ban on organ donation from donors known to be HIV positive.
Get email notifications every time HIV Care Today is updated.
This article was provided by TheBodyPRO.com. HIV Care Today is a multi-author blog featuring people on the frontlines of HIV treatment, prevention and patient/client care. This blog serves as a platform for these health care professionals to discuss the everyday challenges of their jobs, recent developments in their fields and issues relevant to the evolution of HIV/AIDS care.
Subscribe to This Blog:
 | By RSS  |
 | |
Bloggers and Contributors:
- David Fawcett, Ph.D., L.C.S.W.
- Lisa Fitzpatrick, M.D., M.P.H.
- Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
- Paul E. Sax, M.D.
- Nelson Vergel, B.S.Ch.E., M.B.A.
Recent Posts:
May 6, 2013 - MyHIVclinic.org: Rethinking How We Learn to Practice HIV Medicine
May 2, 2013 - How to Interpret Medical Breakthroughs in the Mainstream Media
April 30, 2013 - Lost and Found: Helping Patients Develop Emotional Resilience: A Blog Entry by David Fawcett, Ph.D., L.C.S.W.
April 29, 2013 - Data Safety Monitoring Board Closes HIV Vaccine Study -- the End of Adenovirus as a Vaccine Vector?
A Brief Disclaimer:
The opinions expressed by TheBodyPRO.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBodyPRO.com itself.
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
